Underwriters exercise over-allotments on Tranzyme IPO

Tranzyme Pharma said in a written statement Thursday that the underwriters of its recently completed initial public offering have partially exercised their option to purchase shares of common stock to cover over-allotments. The sale of the additional …
See all stories on this topic »